Identification of peptides presented by HLA class I molecules on cervical cancer cells with HPV-18 infection (original) (raw)

Identification of two homologous antigenic peptides derived from L1 HPV16 and 18 proteins specific for the HLA-B*3901 allele

Claudia Hernández Montes

Archives of Virology, 2002

View PDFchevron_right

Identification of two homologous antigenic peptides derived from L1 HPV-16 and 18 proteins specific for the HLA-B*3901 allele

BENNY WEISS, Jorge Hernández-Montes, Alberto Monroy-garcia

Archives of Virology, 2002

View PDFchevron_right

Identification of a naturally processed HLA-A*0201 HPV18 E7 T cell epitope by tumor cell mediatedin vitro vaccination

Andreas Kaufmann

International Journal of Cancer, 2003

View PDFchevron_right

Identification of a naturally processed HLA A0201‐restricted viral peptide from cells expressing human papillomavirus type 16 E6 oncoprotein

Alfonso Ferrara

European Journal of Immunology, 1994

View PDFchevron_right

Papillomavirus-E7 Peptides Provided by Human Recognize HLA-DR-Restricted Lymphocytes in Cervical Cancer Tumor-Infiltrating + CD4

Markus Maeurer

2010

View PDFchevron_right

Human Papillomavirus Type 33 E7 Peptides Presented by HLA-DR*0402 to Tumor-Infiltrating T Cells in Cervical Cancer

Markus Maeurer

Journal of Virology, 2000

View PDFchevron_right

Natural T-helper immunity against human papillomavirus type 16 (hpv16) e7-derived peptide epitopes in patients with hpv16-positive cervical lesions: Identification of 3 human leukocyte antigen class ii-restricted epitopes

Tom h.m. Ottenhoff

International Journal of Cancer, 2001

View PDFchevron_right

Human T-cell responses to HLA-A-restricted high binding affinity peptides of human papillomavirus type 18 proteins E6 and E7

Cornelis Melief

Clinical cancer research : an official journal of the American Association for Cancer Research, 2001

View PDFchevron_right

Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells

Daphne Jansen, Mariet Feltkamp, Martin Kast

European Journal of Immunology, 1993

View PDFchevron_right

Differential binding of viral peptides to HLA-A2 alleles. Implications for human papillomavirus type 16 E7 peptide-based vaccination against cervical carcinoma

Remco Brandt, Martin Kast

European Journal of Immunology, 1999

View PDFchevron_right

A Conserved E7-derived Cytotoxic T Lymphocyte Epitope Expressed on Human Papillomavirus 16-transformed HLA-A2+ Epithelial Cancers

Karen Anderson

Journal of Biological Chemistry, 2010

View PDFchevron_right

Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I–II trial

Gert Fleuren

European Journal of Cancer, 1999

View PDFchevron_right

A Comprehensive in Silico Analysis for Identification of Immunotherapeutic Epitopes of HPV-18

Parikipandla sridevi

International Journal of Peptide Research and Therapeutics

View PDFchevron_right

Direct identification of an HPV-16 tumor antigen from cervical cancer biopsy specimens

Sun Lee, Derin Keskin

Frontiers in immunology, 2011

View PDFchevron_right

Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate HPV type 16-induced tumors

W. Martin Kast

2013

View PDFchevron_right

Design of a Synthetic Long Peptide Vaccine Targeting HPV-16 and -18 Using Immunoinformatic Methods

Corina VERNIC

Pharmaceutics

View PDFchevron_right

Cytotoxic T-Lymphocyte Responses to Human Papillomavirus Type 16 E5 and E7 Proteins and HLA-A*0201-Restricted T-Cell Peptides in Cervical Cancer Patients

岱瑋 劉

Journal of Virology, 2007

View PDFchevron_right

A synthetic chimeric peptide harboring human papillomavirus 16 cytotoxic T lymphocyte epitopes shows therapeutic potential in a murine model of cervical cancer

Chandresh Sharma

Immunologic Research, 2013

View PDFchevron_right

Purification and HPLC-MS analysis of a naturally processed HCMV-derived peptide isolated from the HEK-293T/HLA-E+/Ul40+ cell transfectants and presented at the cell surface in the context of HLA-E

Gabriella Pietra, Enrico Millo

Journal of Immunological Methods, 2007

View PDFchevron_right

Identification of promiscuous HPV16-derived T helper cell epitopes for therapeutic HPV vaccine design

Andreas Kaufmann

International Journal of Cancer, 2014

View PDFchevron_right

HLA-A2-restricted peripheral blood cytolytic T lymphocyte response to HPV type 16 proteins E6 and E7 from patients with neoplastic cervical lesions

Klaus Heeg

Cancer Immunology, Immunotherapy, 1996

View PDFchevron_right

HPV16 L1E7 chimeric virus-like particles induce specific HLA-restricted T cells in humans afterin vitro vaccination

Andreas Kaufmann

International Journal of Cancer, 2001

View PDFchevron_right

Immunization of mice by a multimeric L2-based linear epitope (17-36) from HPV type 16/18 induced cross reactive neutralizing antibodies

Arash Arashkia

View PDFchevron_right

Use of Fluorogenic Histocompatibility Leukocyte Antigen-A*0201/HPV 16 E7 Peptide Complexes to Isolate Rare Human Cytotoxic T-Lymphocyte- recognizing Endogenous Human Papillomavirus Antigens1

Alison Fiander

2000

View PDFchevron_right